Compare McCormick & Company, Incorporated (MKC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Smith & Nephew plc — how do they compare? McCormick & Company, Incorporated trades at $45.94 (market cap $12.20B), while Smith & Nephew plc trades at $27.21 (market cap $11.31B). The key difference: McCormick & Company, Incorporated and Smith & Nephew plc are close in size by market cap, and McCormick & Company, Incorporated pays the higher dividend (4.24%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Smith & Nephew plc for 120 Days on average.
| MKC | SNN | |
|---|---|---|
Market Cap | $12.20B | $11.31B |
Volume | 4,117,008 | 1,050,005 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $37.17 |
52-Week Low | $44.14 | $26.42 |
Typical Hold Time | 67 Days | 120 Days |
Enterprise Value | $16.88B | $14.35B |
Dividend Yield | 4.24% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.94, up 1.19% today, with a bearish technical signal but strong fundamentals. Recent Q3 2026 earnings beat estimates with $0.86 EPS, driven by 17% sales growth and margin expansion. The stock appears undervalued with a P/E of 8.18 and offers a dividend yield. Cash flow trends show operational strength despite a net outflow in 2025.
The outlook is mixed: solid earnings growth and a $53.50 consensus price target suggest upside, but technical weakness and competitive pressures pose risks. Investor sentiment is cautious with a 'Hold' analyst consensus. Key catalysts include continued margin improvement and integration of recent acquisitions.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
